Anti-CD33 CAR-NK cell therapy (Sichuan Kelun-Biotech)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAnti-CD33 CAR-NK cell therapy (Sichuan Kelun-Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsGene transferenceNatural killer cell receptors modulators

TargetsMyeloid cell surface antigen CD33Natural killer cell receptors

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A